Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis

(2013) B. Flourié et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The burden of inflammatory bowel disease in Europe

(2013) Johan Burisch et al.   Journal of Crohns & Colitis

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers

(2011) James Buchanan et al.   Journal of Crohns & Colitis

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial

(2009) Mark P. Connolly et al.   Journal of Crohns & Colitis

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

(2009) J.F. Rahier et al.   Journal of Crohns & Colitis

A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis

(2009) Chris D. Poole et al.   Journal of Crohns & Colitis

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

(2008) W Kruis et al.   GUT

Population-based controlled study of social support, self-perceived stress, activity and work issues, and access to health care in inflammatory bowel disease

(2008) Linda Rogala et al.   INFLAMMATORY BOWEL DISEASES

An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial

(2008) Mark P. Connolly et al.   Journal of Crohns & Colitis